A share price of Gilead Sciences, Inc [GILD] is currently trading at $113.35, down -0.56%. An important factor to consider is whether the stock is rising or falling in short-term value. The GILD shares have lost -2.32% over the last week, with a monthly amount glided 17.90%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Gilead Sciences, Inc [NASDAQ: GILD] stock has seen the most recent analyst activity on March 04, 2025, when Oppenheimer reiterated its Outperform rating and also boosted its price target to $132 from $115. Previously, Deutsche Bank upgraded its rating to Buy on February 18, 2025, and kept the price target unchanged to $120. On February 13, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $108 on the stock. Morgan Stanley upgraded its rating to a Overweight and increased its price target to $113 on January 10, 2025. Wolfe Research started tracking with a Outperform rating for this stock on November 15, 2024, and assigned it a price target of $110. In a note dated November 14, 2024, Citigroup initiated an Buy rating and provided a target price of $125 on this stock.
Gilead Sciences, Inc experienced fluctuations in its stock price throughout the past year between $62.07 and $119.96. Currently, Wall Street analysts expect the stock to reach $107.63 within the next 12 months. Gilead Sciences, Inc [NASDAQ: GILD] shares were valued at $113.35 at the most recent close of the market. An investor can expect a potential drop of -5.05% based on the average GILD price forecast.
Analyzing the GILD fundamentals
Trailing Twelve Months sales for Gilead Sciences, Inc [NASDAQ:GILD] were 28.73B which represents 6.39% growth. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.29%, Pretax Profit Margin comes in at 0.02%, and Net Profit Margin reading is 0.02%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.03 and Total Capital is 0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 112.21 points at the first support level, and at 111.07 for the second support level. However, for the 1st resistance point, the stock is sitting at 114.98, and for the 2nd resistance point, it is at 116.60.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Gilead Sciences, Inc [NASDAQ:GILD] is 1.60. On the other hand, the Quick Ratio is 1.45, and the Cash Ratio is 0.83. Considering the valuation of this stock, the price to sales ratio is 4.91, the price to book ratio is 7.31 and price to earnings (TTM) ratio is 308.77.
Transactions by insiders
Recent insider trading involved Dickinson Andrew D, Chief Financial Officer, that happened on Mar 10 ’25 when 17929.0 shares were sold. Officer, ANDREW DICKINSON completed a deal on Mar 10 ’25 to buy 17929.0 shares. Meanwhile, Officer MERDAD V PARSEY bought 21910.0 shares on Mar 03 ’25.
